Bank of Nova Scotia
TEVA icon

Bank of Nova Scotia’s Teva Pharmaceuticals TEVA Stock Holding History

Bank of Nova Scotia’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-39,346
Closed -$555K – 1071
2024
Q1 		$555K Sell
39,346
-1,000
-2% -$12.6K ﹤0.01% 837
2023
Q4 		$421K Sell
40,346
-18,300
-31% -$171K ﹤0.01% 872
2023
Q3 		$598K Buy
58,646
+417
+0.7% +$3.88K ﹤0.01% 777
2023
Q2 		$438K Buy
58,229
+26
+0% +$211 ﹤0.01% 843
2023
Q1 		$515K Hold
58,203
– – ﹤0.01% 830
2022
Q4 		$531K Buy
58,203
+400
+0.7% +$3.49K ﹤0.01% 905
2022
Q3 		$466K Hold
57,803
– – ﹤0.01% 985
2022
Q2 		$434K Sell
57,803
-300
-0.5% -$2.61K ﹤0.01% 1030
2022
Q1 		$546K Buy
58,103
+2,600
+5% +$21.7K ﹤0.01% 1028
2021
Q4 		$443K Sell
55,503
-563
-1% -$5.08K ﹤0.01% 1106
2021
Q3 		$546K Buy
56,066
+750
+1% +$7.02K ﹤0.01% 977
2021
Q2 		$548K Buy
55,316
+2,829
+5% +$29.9K ﹤0.01% 952
2021
Q1 		$606K Sell
52,487
-365
-0.7% -$4.18K ﹤0.01% 888
2020
Q4 		$510K Buy
52,852
+23,849
+82% +$228K ﹤0.01% 903
2020
Q3 		$261K Sell
29,003
-300
-1% -$3.17K ﹤0.01% 963
2020
Q2 		$361K Sell
29,303
-52,879
-64% -$598K ﹤0.01% 810
2020
Q1 		$738K Buy
82,182
+58,179
+242% +$596K ﹤0.01% 722
2019
Q4 		$235K Sell
24,003
-1,800
-7% -$16.1K ﹤0.01% 886
2019
Q3 		$178K Buy
25,803
+7,800
+43% +$59.8K ﹤0.01% 879
2019
Q2 		$166K Hold
18,003
– – ﹤0.01% 830
2019
Q1 		$282K Buy
18,003
+1,100
+7% +$19.4K ﹤0.01% 792
2018
Q4 		$261K Buy
16,903
+2,800
+20% +$57.4K ﹤0.01% 803
2018
Q3 		$304K Buy
14,103
+1,800
+15% +$41.8K ﹤0.01% 808
2018
Q2 		$299K Buy
+12,303
New +$251K ﹤0.01% 806
2017
Q3 		– Sell
-6,903
Closed -$229K – 985
2017
Q2 		$229K Buy
+6,903
New +$214K ﹤0.01% 909
2016
Q1 		– Sell
-6,334
Closed -$419K – 777
2015
Q4 		$419K Buy
+6,334
New +$391K ﹤0.01% 539

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
IAM
Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of Nova Scotia's TEVA Position: Q2 2024 in Review

Bank of Nova Scotia sold out of Teva Pharmaceuticals (TEVA) in Q2 2024, closing a stake of 39,346 shares — an estimated $555K sold.

Bank of Nova Scotia first reported a position in TEVA in Q4 2015 and held it in 26 quarters. The position peaked at $738K in Q1 2020. 534 funds tracked by Wall St. Rank hold TEVA as of Q2 2024.

  • Bank of Nova Scotia reported no remaining Teva Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Bank of Nova Scotia sold 39,346 Teva Pharmaceuticals shares in Q2 2024, an estimated $555K.
  • Bank of Nova Scotia first reported a position in Teva Pharmaceuticals in Q4 2015 and held it in 26 quarters.
  • Bank of Nova Scotia's Teva Pharmaceuticals position peaked at $738K in Q1 2020.
  • 534 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2024.

Based on Bank of Nova Scotia's 13F filing for Q2 2024, filed 14 Aug 2024.